CompaniesHealthcareHealthcarePharmaceuticals & Biotechnology

KERALA AYURVEDA LTD.

Healthcare › Pharmaceuticals & Biotechnology
171.30
at close · 21 Sept 2026
3.70 (-2.11%)

Latest filings

  1. Newspaper ad confirms dispatch of Kerala Ayurveda FY26 Annual Report · Compliance
  2. Kerala Ayurveda 34th AGM notice with preferential share issue to promoter firm · Board & Shareholder Meetings
  3. 34th AGM notice and FY26 annual report filed; preferential issue on agenda · Board & Shareholder Meetings
  4. Newspaper notice for 34th AGM and Annual Report 2025-26 dispatch · Compliance
  5. Preferential issue of 7.2 lakh shares to promoter group for debt conversion · Fund Raising
  6. Board meeting on Sept 4 for preferential share issue and 34th AGM · Board & Shareholder Meetings
  7. Kerala Ayurveda Q1 FY27 results: net loss continues, subsidiary merger approved · Results
  8. Board approves Q1 FY27 results, subsidiary merger and ESOP grant · Results
  9. Board meeting on Aug 12, 2026 to consider Q1 FY27 unaudited results · Results
  10. Filing of quarterly certificate under SEBI Regulation 74(5) for Q1 FY27 · Compliance
  11. Trading window closed from June 30 for Q1 results · Compliance
  12. Newspaper publication announcement by Kerala Ayurveda · Compliance
  13. Revised Corporate announcement Pursuant to the query raised from BSE · Management Changes
  14. Resignation of Independent Director · Management Changes
  15. Intimation under regulation 30(5) · Compliance
  16. Appointment of Company secretary and Compliance officer · Management Changes
  17. Appointment of New Company Secretary · Management Changes
  18. ASCR 2026 · Compliance
  19. Newspaper publication - Financial Results · Compliance
  20. Press Release · Business Updates
  21. Appointment of Internal Auditor and Cost Auditor · Management Changes
  22. Financial Results for the Year Ended 31st March 2026 · Results
  23. Outcome of Board meeting held on 25th May 2026 · Results
  24. Kerala Ayurveda Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 25/05/2026 ,inter alia, to consider and approve Board meeting on 25th May 2026 · Board & Shareholder Meetings
  25. <b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=''1px''><tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> .... · Compliance
  26. Announcement Under Regulation 30 (LODR) · General
  27. Clarification on Price Movement · General
  28. The Exchange has sought clarification from Kerala Ayurveda Ltd on April 8, 2026 with reference to significant movement in price, in order to ensure that investors have latest relevant information .... · Regulatory & Legal
  29. Certificate under Reg.75(5) of SEBI(D)Regulations, 2018 · Compliance
  30. Closure of Trading window · Compliance
  31. Outcome of Board on 25-03-2026 · Board & Shareholder Meetings
  32. Kerala Ayurveda Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 25/03/2026 ,inter alia, to consider and approve Pursuant to Regulation 29 (1)(d) .... · Board & Shareholder Meetings
  33. Allotment of equity shares on preferential basis · Fund Raising
  34. EGM- Scrutinizer''s Report · Board & Shareholder Meetings
  35. Proceedings of EGM held on 14th March 2026 · Board & Shareholder Meetings
  36. News Paper publication · Compliance
  37. Extraordinary General Meeting of Kerala Ayurveda Limited to be convened on 14 March 2026 · Board & Shareholder Meetings
  38. News paper publication · Compliance
  39. Press Release · Strategic Transactions
  40. Preferential Issue · Fund Raising
  41. Grant of ESOPs · General
  42. Acquisition- Ayurvedagram · Strategic Transactions
  43. Financial Results for the quarter ended 31st December, 2025 · Results
  44. Outcome of Board meeting held on 12th February 2026 · Board & Shareholder Meetings
  45. Kerala Ayurveda Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/02/2026 ,inter alia, to consider and approve the quarterly results for .... · Results
  46. Settlement Order of SEBI · Regulatory & Legal
  47. Announcement under regulation 30 (LODR) Resignation of Company Secretary · Management Changes
  48. Postal Ballot Voting results · Board & Shareholder Meetings
  49. Please find attached the voting results and scrutinizers'' report for the Postal ballot notice issued on December 19, 2025. This is to further inform you that all the resolutions contained .... · Board & Shareholder Meetings
  50. Compliances - Certificate under Reg.74(5) of SEBI(DP)Regulations 2018 · Compliance
All filings ↓
Ask Nexa about KERALA AYURVEDA LTD.

Snapshot

What the business is, and whether it's a good one at a fair price.

A Pharmaceuticals & Biotechnology company listed on BSE, reporting revenue of ₹136 Cr over the trailing twelve months.

Market Cap
₹223 Cr
P / E (TTM)
7.5×
EV / EBITDA
Div Yield
Growth
17.3%
Revenue 5y CAGR
PAT — · EBITDA —
Quality
5.7%·
ROCE (5y median)
ROE -5.4% · margin -2.7%
Leverage
5.43·
Debt / Equity · high
Net debt ₹75 Cr
Revenue FY21→FY26
2.2×
Margin 4.2 pts
₹59 Cr → ₹131 Cr
Moves on a normal day
1.89%·
Median daily move
Last 268 sessions · filing days run larger
Where it sits among 185 Pharmaceuticals peersBar = share of peers beaten · tick = industry median · latest reported figures
P/E (TTM)#18/170
P/B#154/164
ROCE#175/183
ROE#170/171
Debt / Equity#171/171
EBITDA margin#159/165
Revenue growth#82/161
Profit growth#157/158

Scorecard

Measured from the filed financials, judged against its Pharmaceuticals peers · as of FY26 — not investment advice

Strengths
Revenue compounding 17% a year over 5 years
Concerns
Erratic profits — up in only 1 of the last 5 years
Returns on capital 5.7% (5-year median)
#175 of 183 in Pharmaceuticals on the latest reported figures · down from -0.5% in FY21
Carries more debt than its peers — 5.43× equity
lower than 0% of its 171 Pharmaceuticals peers

Charts

How has the market priced it — with filings on the timeline?

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Peers

How does it stack up on valuation, returns and growth?

Loading peers…

Financials

Quarterly & annual P&L, balance sheet, cash flow, ratios and segments.

Loading financials…

Ownership

Who owns it — and is the promoter stake clean?

Loading shareholding

Sign up to see the full company file

Governance, sustainability, compliance, earnings calls, presentations, events, reactions and the full filings feed — free with an account.

Common questions

Answered from KERALA AYURVEDA LTD.'s filed financials and exchange disclosures

What does KERALA AYURVEDA LTD. do?

KERALA AYURVEDA LTD. is a Pharmaceuticals & Biotechnology company listed on BSE.

Is KERALA AYURVEDA LTD. profitable?

No. Over the trailing twelve months KERALA AYURVEDA LTD. reported a net loss of ₹26 Cr on revenue of ₹136 Cr.

Does KERALA AYURVEDA LTD. pay a dividend?

Not in the latest reported year — KERALA AYURVEDA LTD.'s dividend payout for FY26 was nil.

Is KERALA AYURVEDA LTD. debt-free?

No. Debt stands at 5.43× equity, and it carries net debt of ₹75 Cr. That is lower than 0% of its 171 Pharmaceuticals peers.

Is KERALA AYURVEDA LTD. expensive compared with its peers?

On trailing P/E, KERALA AYURVEDA LTD. ranks 18 of 170 in Pharmaceuticals — cheaper than 90% of them, against an industry median of 29.6×. This is a position, not a valuation judgement.

How much does the KERALA AYURVEDA LTD. share price move in a day?

On a typical session KERALA AYURVEDA LTD. moves 1.89% — that is the median absolute close-to-close move across its last 268 trading days. Announcement days are routinely larger.

Where can I track KERALA AYURVEDA LTD.'s announcements?

Every NSE and BSE filing by KERALA AYURVEDA LTD. appears on this page, AI-summarised, alongside the price reaction that followed it. Follow the company to get each new filing on WhatsApp within minutes.

Figures are as last reported and may lag the latest filing. Not investment advice.